Thus, we were able to hypothesize that PEM might be used to treat CRC by targeting the E948 site of GART to inhibit its methyltransferase activity, so as to suppress the RUVBL1‐mediated β‐catenin signaling pathway. The gene discussed is RUVBL1; the disease is colorectal carcinoma.